에스티팜

237690KOSDAQ의약품 제조업

56.8 / 100

Reference Date: 2026-06-10

Financial Score21.5 / 40

News Sentiment17.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Plunged 23.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ESTEPAF, originally established as Samcheonri Pharmaceutical in 1983 and later acquired by Dong-A Ssosiogroup in 2010, has expanded into the oligonucleotide CDMO sector, achieving global top 3 production capacity. It entered the mRNA business in 2020, completed the second oligo facility in 2025, and is advancing clinical trials for its self-developed drugs STP0404 (HIV treatment) and STP1002 (cancer treatment). The company has integrated CRO and CDMO services into a one-stop system, enhancing its pharmaceutical development capabilities through global partnerships.

Number of Employees

1,560people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

43.64Industry Average 11.930.0Point

3.7x industry avg (risky)

PBR

4.15Industry Average 0.890.0Point

4.7x industry avg (risky)

ROE

9.96Industry Average 4.017.0Point

2.5x industry avg (excellent)

Debt Ratio

4.18Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 7.4% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 4Neutral 2Negative 1Average Sentiment Score 69.3

Negative
'삼전닉스 살 걸' 늦은 후회…바이오주로 씻어낼 수 있을까 [B급기자의...
고금리 환경으로 제약바이오 산업이 어려움을 겪고 있어 에스티팜의 성장에 부정적 영향이 예상됩니다.
Positive
에스티팜, RNA 원료 수요 확대에…중장기 실적 확대 기대감 [Why ...
에스티팜의 RNA 치료제 관련 수요 증가로 인해 중장기 실적 개선 기대감이 높아짐.
Neutral
[바이오스냅] 에스티팜, UN 글로벌콤팩트에 가입
에스티팜의 UN 글로벌콤팩트 가입 소식은 기업의 사회적 책임 강화를 보여주나, 직접적인 재무 영향은 제한적입니다.

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 118,100Won52-week high 168,70052-week low 76,500

1-month return0.0Point

1m -23.21% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral[기재정정]사업보고서 (2025.12)2026-06-02
Neutral분기보고서 (2026.03)2026-05-15
Neutral기업설명회(IR)개최2026-05-14